HolderBook

PFM Health Sciences, LP

Reported holdings as of Q2 2026, from 31 quarterly filings.

This filer last reported in Q2 2026; the most recent quarter on file across all filers is Q3 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1442756
Reported value
$1.2B
Positions
96
Top 10 weight
33.9%
Filed
2026-08-14
Days after quarter end
45

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
ASCENDIS PHARMA A/SASND$62.2M233,1715.34%-newNEW
AXSOME THERAPEUTICS INCAXSM$53.8M219,5964.61%+0.54pp17q-16.9%-$10.9M
ELI LILLY & COLLY$47.1M39,2584.04%-1.47pp23q-40.3%-$31.8M
JAZZ PHARMACEUTICALS PLCJAZZ$38.7M160,7683.32%+0.25pp3q-9.8%-$4.2M
HUMANA INCHUM$37.5M94,3753.22%-newNEW
UNITEDHEALTH GROUP INCUNH$36.7M88,2763.15%+1.72pp3q+52.1%+$12.6M
NEUROCRINE BIOSCIENCES INCNBIX$36.0M213,4073.09%+0.50pp5q-1.1%-$382.7K
INHIBRX BIOSCIENCES INCINBX$29.2M308,3852.51%+0.63pp9q+1.0%+$279.9K
UNITED THERAPEUTICS CORP DELUTHR$27.1M49,9912.32%-4.02pp5q+25.6%+$5.5M
REVOLUTION MEDICINES INCRVMD$26.8M143,2222.30%+1.05pp4q+1.7%+$459.2K
ICON PUB LTD COICLR$23.7M136,4822.03%+1.45pp29q+137.4%+$13.7M
TENET HEALTHCARE CORPTHC$23.7M126,5722.03%-4.83pp25q-68.2%-$50.9M
EDWARDS LIFESCIENCES CORPEW$22.7M250,4531.94%+0.09pp31q-1.6%-$367.0K
WATERS CORPWAT$22.4M59,8251.93%+0.85pp10q+50.5%+$7.5M
CENTENE CORP DEL PUTCNC$21.6M248,8671.86%+1.07pp4q-5.5%-$1.3M
PENUMBRA INCPEN$19.0M60,2211.63%-2.55pp31q-56.9%-$25.1M
BRIDGEBIO PHARMA INCBBIO$18.9M253,3581.62%-0.13pp7q-1.7%-$326.9K
STRYKER CORPORATIONSYK$17.8M56,6371.53%+0.87pp3q+157.9%+$10.9M
METTLER TOLEDO INTERNATIONALMTD$17.0M13,3441.46%-newNEW
INDIVIOR PHARMACEUTICALS INCINDV$16.5M401,2081.41%-0.18pp2q-30.2%-$7.1M
MERCK & CO INCMRK$16.3M127,1181.40%-newNEW
CYTOKINETICS INCCYTK$16.3M191,6861.40%-newNEW
LANTHEUS HLDGS INCLNTH$16.2M146,4031.39%-newNEW
COOPER COS INCCOO$15.8M220,8901.36%+0.25pp4q+30.1%+$3.7M
MADRIGAL PHARMACEUTICALS INCMDGL$15.7M29,3131.35%-0.28pp3q-14.2%-$2.6M
ACADIA HEALTHCARE COMPANY INACHC$15.5M524,9341.33%+0.09pp2q-9.9%-$1.7M
ORUKA THERAPEUTICS INCORKA$15.1M158,8251.30%+0.52pp2q-8.7%-$1.4M
OSCAR HEALTH INCOSCR$14.8M519,0161.27%+0.75pp13q+3.8%+$547.0K
THERMO FISHER SCIENTIFIC INCTMO$14.3M28,4961.23%+0.56pp4q+92.1%+$6.9M
CVS HEALTH CORPCVS$14.2M137,4571.22%-newNEW
MERIT MED SYS INCMMSI$13.7M197,0381.17%+0.15pp2q+21.3%+$2.4M
PRAXIS PRECISION MEDICINES IPRAX$12.9M38,5751.11%+0.07pp11q+8.9%+$1.1M
CELLDEX THERAPEUTICS INC NEWCLDX$12.8M342,7511.09%+0.15pp3q+5.5%+$662.1K
NOVO-NORDISK A SNVO$12.7M265,0161.09%+0.43pp2q+34.4%+$3.3M
INTEGER HLDGS CORPITGR$11.8M126,6691.02%-0.07pp3q-6.2%-$786.1K
DIANTHUS THERAPEUTICS INCDNTH$11.8M121,2221.01%-0.30pp4q-29.6%-$5.0M
DEFINIUM THERAPEUTICS INCDFTX$11.7M249,0201.01%+0.65pp2q+21.3%+$2.1M
GILEAD SCIENCES INCGILD$11.5M90,8580.98%-newNEW
RHYTHM PHARMACEUTICALS INCRYTM$11.3M101,5500.97%-0.12pp4q-25.7%-$3.9M
SCHEIN HENRY INCHSIC$11.2M134,4230.96%-0.07pp2q-12.2%-$1.6M
ARROWHEAD PHARMACEUTICALS INARWR$10.7M131,6670.92%+0.55pp2q+104.8%+$5.5M
TANGO THERAPEUTICS INCTNGX$10.2M326,0470.87%+0.10pp2q-19.7%-$2.5M
TELEFLEX INCORPORATEDTFX$10.1M79,7080.87%-newNEW
CENCORA INC CALLCOR$10.0M7,3850.86%-newNEW
VIKING THERAPEUTICS INCVKTX$10.0M255,3300.85%+0.07pp5q-3.0%-$303.3K
BRIGHTSPRING HEALTH SVCS INCBTSG$9.9M141,9140.85%+0.12pp3q-24.2%-$3.2M
VERA THERAPEUTICS INCVERA$9.6M224,2890.83%+0.18pp4q+28.3%+$2.1M
ROIVANT SCIENCES LTDROIV$9.5M268,0080.81%+0.29pp2q+29.2%+$2.1M
CG ONCOLOGY INCCGON$9.1M128,2860.78%-0.24pp4q-22.7%-$2.7M
AMNEAL PHARMACEUTICALS INCAMRX$8.3M480,7150.71%-0.34pp4q-48.3%-$7.8M
EUPRAXIA PHARMACEUTICALS INCEPRX$8.0M1,210,6610.69%+0.33pp2q+123.8%+$4.4M
IRHYTHM HOLDINGS INCIRTC$7.8M65,1960.67%-newNEW
KODIAK SCIENCES INCKOD$7.5M193,3150.65%+0.25pp2q+68.5%+$3.1M
ABBOTT LABORATORIESABT$7.5M82,2300.64%-0.67pp2q-41.4%-$5.3M
WEST PHARMACEUTICAL SVSC INCWST$7.4M20,7330.64%-newNEW
TAKEDA PHARMACEUTICAL CO LTDTAK$7.1M444,1730.61%-newNEW
HINGE HEALTH INCHNGE$6.9M82,8600.59%-newNEW
ARCUTIS BIOTHERAPEUTICS INCARQT$6.3M242,0690.54%-newNEW
INTEGRA LIFESCIENCES HLDGS CIART$6.3M348,7460.54%-newNEW
ILLUMINA INCILMN$6.2M35,0400.53%+0.20pp2q+21.4%+$1.1M
MEIRAGTX HLDGS PLCMGTX$6.2M455,2860.53%-newNEW
OCULIS HOLDING AGOCS$6.0M436,0420.52%-newNEW
NATERA INCNTRA$6.0M22,0770.51%-0.58pp2q-63.2%-$10.3M
ABIVAX SAABVX$5.8M43,2640.49%+0.22pp3q+62.3%+$2.2M
GUARDANT HEALTH INCGH$5.5M36,7010.47%-newNEW
CELCUITY INCCELC$5.5M52,1550.47%-newNEW
BELITE BIO INCBLTE$5.4M34,8030.46%-0.40pp3q-41.4%-$3.8M
STRUCTURE THERAPEUTICS INCGPCR$4.9M91,5500.42%-0.13pp6q-27.6%-$1.9M
ARCUS BIOSCIENCES INCRCUS$4.7M152,1290.40%-newNEW
CHARLES RIV LABS INTL INCCRL$4.3M18,7470.36%-newNEW
ELANCO ANIMAL HEALTH INCELAN$4.2M172,4890.36%-newNEW
ARGENX SEARGX$4.2M4,4820.36%+0.05pp17q-1.2%-$49.2K
BIO RAD LABS INCBIO$4.1M13,9950.35%-newNEW
SPYRE THERAPEUTICS INCSYRE$4.1M46,2170.35%-newNEW
MBX BIOSCIENCES INCMBX$3.9M70,9710.34%+0.14pp4q-1.3%-$50.9K
MIRUM PHARMACEUTICALS INCMIRM$3.7M31,5360.32%-newNEW
CULLINAN THERAPEUTICS INCCGEM$3.5M192,4420.30%+0.01pp3q-15.4%-$636.7K
COMPASS PATHWAYS PLCCMPS$3.5M247,5890.30%-0.39pp17q-81.9%-$15.8M
HCA HEALTHCARE INCHCA$3.2M8,2950.28%-0.50pp16q-37.9%-$2.0M
CAPRICOR THERAPEUTICS INCCAPR$2.9M122,2210.25%-0.09pp2q-1.3%-$38.8K
DENALI THERAPEUTICS INCDNLI$2.6M100,9660.22%-newNEW
SYNDAX PHARMACEUTICALS INCSNDX$2.6M118,4220.22%-0.30pp4q-51.7%-$2.8M
AMYLYX PHARMACEUTICALS INCAMLX$2.6M143,7000.22%+0.04pp6q-1.1%-$28.3K
TARSUS PHARMACEUTICALS INCTARS$2.6M40,5790.22%-0.29pp3q-49.4%-$2.5M
OUTSET MED INCOM$2.5M582,1220.22%+0.01pp6q-2.1%-$54.0K
OMADA HEALTH INCOMDA$2.5M114,4420.22%-newNEW
ERASCA INCERAS$2.5M134,0880.21%-newNEW
BIOCRYST PHARMACEUTICALS INCBCRX$2.1M207,3570.18%-newNEW
OMNICELL COMOMCL$2.0M49,0400.17%-newNEW
CVRX INCCVRX$1.9M369,5720.16%-newNEW
HIMS & HERS HEALTH INCHIMS$1.7M49,4540.15%-newNEW
MINERALYS THERAPEUTICS INCMLYS$1.7M62,4180.14%-0.21pp3q-56.3%-$2.2M
TECTONIC THERAPEUTIC INCTECX$1.6M45,6310.13%flat3q-1.1%-$17.1K
UNIQURE NVQURE$1.2M26,3960.10%+0.04pp10q-38.1%-$748.0K
REZOLUTE INCRZLT$661.9K127,2890.06%+0.02pp5q-1.1%-$7.5K
CARIBOU BIOSCIENCES INCCRBU$624.2K354,6870.05%-0.11pp20q-63.0%-$1.1M

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 67.4%Medical Devices 11.7%Insurance 9.5%Healthcare Services 7.5%Wholesale & Distribution 1.8%Other sectors 2.0%
 
SectorValueShare
Biotech & Pharma$785.8M67.4%
Medical Devices$136.8M11.7%
Insurance$110.6M9.5%
Healthcare Services$87.7M7.5%
Wholesale & Distribution$21.3M1.8%
Other sectors$23.2M2.0%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q2 2026+24.7%+14.8%+9.8%89%
Q1 2026-5.7%-4.6%-1.1%96%
Q4 2025+20.4%+2.4%+18.1%94%
Q3 2025+7.4%+7.8%-0.4%96%
Q2 2025+1.8%+10.5%-8.6%96%
Q1 2025+2.6%-4.6%+7.1%88%
Q4 2024-11.8%+2.1%-13.9%97%
Q3 2024+3.4%+5.4%-2.1%96%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$1.2B963322411633.9%45
Q1 2026$1.1B792134191944.8%45
Q4 2025$1.0B773013342342.8%48
Q3 2025$1.3B702616241249.3%45
Q2 2025$1.2B561713242653.5%45
Q1 2025$1.4B651117182454.4%45
Q4 2024$1.6B78229261851.1%45
Q3 2024$1.8B741114231449.9%45
Q2 2024$2.0B77924131646.4%45
Q1 2024$2.1B84251616440.9%44
Q4 2023$1.7B63915271745.7%45
Q3 2023$2.1B71721191634.8%45
Q2 2023$2.6B801623161033.7%45
Q1 2023$2.3B74922241438.5%45
Q4 2022$2.8B791417261639.4%45
Q3 2022$2.8B811324131133.3%45
Q2 2022$2.6B792121121034.1%46
Q1 2022$2.7B681017151336.1%46
Q4 2021$2.9B711210232635.6%45
Q3 2021$3.4B852213161733.7%46
Q2 2021$3.2B801418121436.5%47
Q1 2021$3.3B802428222037.0%47
Q4 2020$2.8B762818162235.8%50
Q3 2020$2.2B702221152340.6%47
Q2 2020$1.9B712915211837.8%45
Q1 2020$1.2B602714192437.5%45
Q4 2019$2.1B57206303549.2%45
Q3 2019$3.4B722518273842.1%45
Q2 2019$5.3B852431282940.3%45
Q1 2019$4.5B903619344032.7%45
Q4 2018$3.8B94000030.4%45

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.